Pain News and Research

Latest Pain News and Research

People suffering from chronic pain, emotional distress likely to receive long-term opioid therapy

People suffering from chronic non-cancer pain and severe emotional distress, such as depression, anxiety and substance use, are likely to receive long-term opioid therapy despite a lack of evidence that this treatment helps, reports a new review in General Hospital Psychiatry.

13 Nov 2013

Studies suggest novel therapies for nicotine, heroin and gambling addiction

Studies released today suggest promising new treatments for nicotine and heroin addiction, and further our understanding of pathological gambling and heroin abuse in those suffering chronic pain.

12 Nov 2013

Hebrew University to participate in new European research project on chronic pain

The Hebrew University of Jerusalem is one of 11 universities, medical centers and research institutes in seven countries participating in ncRNAPain, a new European research project that aims at further exploring the biological mechanisms underlying chronic pain.

12 Nov 2013

Nontoxic therapy shows encouraging results in blood samples from lupus patients

Northwestern Medicine- scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

12 Nov 2013

New study stresses importance of studying freezing episodes in Parkinson's patients

A recent study, led by Ryan P. Duncan of Washington University at St. Louis, suggested patients with Parkinson's disease who suffer from freezing episodes are more likely to have impaired balance than those who do not. This is an important discovery as Parkinson's disease typically develops in elderly patients, who cannot afford to be unstable, lose balance and potentially fall, which could result in major injuries.

12 Nov 2013

Viewpoints: Shinseki's efforts haven't yet solved VA's problems; treating children with mental illness is complicated; abuse of painkillers

Just in time for Veterans Day, the embattled secretary of Veterans Affairs, Eric K. Shinseki, announced last week that his department had reduced its backlog of overdue disability claims from more than 600,000 in March to about 400,000. "The trend line is in the right direction," Shinseki told reporters, noting that the VA had cut the number of claims older than a year by 93%. With hundreds of thousands of cases still unresolved, Shinseki hasn't gotten much credit so far - but to the surprise of his critics, he's on track to achieve his goal of eliminating the backlog by 2015. Still, that won't solve all the VA's problems; far from it (Doyle McManus, 11/10).

12 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

Occupational therapist receives $1M grant to develop virtual world programs that help amputees improve skills

Some people use alternate virtual world programs like Second Life- to escape reality, but one researcher is examining whether these same virtual worlds that are used to stimulate the imagination could help amputees develop the skills needed to navigate the real world.

11 Nov 2013

Study shows that different brain regions process different types of fear

What do bullies and sex have in common? Based on work by scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, it seems that the same part of the brain reacts to both.

11 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up).

10 Nov 2013

Report: Postmastectomy pain rated as most troubling symptom by breast cancer survivors

More than 40 percent of 200,000 U.S. women diagnosed with breast cancer every year undergo surgery. Though treatment advances have significantly reduced mortality from breast cancer, a study published in The Journal of Pain reported that persistent postmastectomy pain is rated by survivors as their most troubling symptom. The Journal of Pain is published by the American Pain Society, www.americanpainsociety.org.

8 Nov 2013

Viewpoints: The battle over one woman's medical story; why Mass. didn't see a wave of cancellations; politicians' love of anecdotes

Edie Littlefield Sundby may not have thought she'd ignite a national debate when the stage-4 cancer survivor asked us to publish her Monday op-ed on losing her oncologist due to the Affordable Care Act. But she certainly has, and it's important to understand why. Mrs. Sundby and millions like her must be denied their medical choices if ObamaCare is going to work as its liberal planners intend (11/6).

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Landmark clinical trial of artificial aortic heart valve shows positive results

Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery.

From Medtronic 8 Nov 2013

Longer looks: Bad behavior treatment; end of life decisions

Every week reporter Ankita Rao selects interesting reading from around the Web.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Pain News and Research

Latest Pain News and Research

People suffering from chronic pain, emotional distress likely to receive long-term opioid therapy

Studies suggest novel therapies for nicotine, heroin and gambling addiction

Hebrew University to participate in new European research project on chronic pain

Nontoxic therapy shows encouraging results in blood samples from lupus patients

New study stresses importance of studying freezing episodes in Parkinson's patients

Viewpoints: Shinseki's efforts haven't yet solved VA's problems; treating children with mental illness is complicated; abuse of painkillers

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Occupational therapist receives $1M grant to develop virtual world programs that help amputees improve skills

Study shows that different brain regions process different types of fear

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

Report: Postmastectomy pain rated as most troubling symptom by breast cancer survivors

Viewpoints: The battle over one woman's medical story; why Mass. didn't see a wave of cancellations; politicians' love of anecdotes

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Landmark clinical trial of artificial aortic heart valve shows positive results

Longer looks: Bad behavior treatment; end of life decisions

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Pain News and Research

Latest Pain News and Research

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Newsletters you may be interested in